Daygold launches 12 days of self-care challenge
(WXYZ) — Portland brand, Daygold, has launched a range of first-of-its-kind neurologist formulated tinctures to help you enjoy a brighter life, naturally.
Having researched plants and their benefits for over 25 years, along with being on the team of doctors to get FDA approval on the first cannabis medicine, board-certified neurologist Dr. Ethan Russo designed Daygold to elevate your quality of life through three thoughtful formulas: Restful Night, Calm Mind, and Easy Relief. Daygold utilizes CBD, CBN, CBG, and THC (< .03%), as well as a dozen botanical terpenes to make each formula natural and effective without intoxicating results.
Great days begin with peaceful nights, so Daygold’s Restful Night tincture may help consumers wind down with ease and wake up ready for whatever comes their way. This custom sleepy time blend features Lavender, Clary Sage, Citrus peels, and Eucalyptus to encourage relaxation.
In Calm Mind, aromatic Ylang Ylang works to uplift your mood, while Neroli oil and Ho Wood promote tranquility. The blend also features Lemon to help calm and brighten the mind, because the brand believes a mind at ease makes living in the moment a breeze.
Finally, Daygold designed Easy Relief with the intention of helping people experience an active lifestyle free of discomfort. Infused with soothing Peppermint, calming Ho Wood, and healing Citrus, this blend creates a sense of ease and relief throughout the body and helps support mental and physical well-being.
Each Daygold tincture is physician-formulated and uses 100% natural ingredients, all of which are selected carefully and intentionally for their targeted benefits. Made by people well-respected in their fields, Daygold’s hemp-based blends are non-GMO, vegan-friendly, and triple lab-tested.
Daygold’s 30mL (1 FL oz.) tinctures retail for $99.00 a bottle and include a 30-day supply. Orders can be placed by visiting daygold.com.
Daygold’s 12 Days of Self-Care Challenge
Day 1: Take a walk outside to get some fresh air and see the holiday lights.
Day 2: Try out a 5-minute meditation to center yourself before the hustle and bustle.
Day 3: Tidy and decorate your space to get you in the holiday spirit.
Day 4: Write down a list of all the people you’re grateful for this holiday season.
Day 5: While holiday shopping for others, treat yourself to a self-care item.
Day 6: Make an essential oil blend featuring holiday scents like cinnamon, peppermint, frankincense, or cedarwood.
Day 7: Head to bed early. For extra help, try Daygold’s Restful Night CBD Oil.
Day 8: Listen to your favorite holiday playlist for 30 minutes while you work.
Day 9: Have a cozy date at home with candles, warm comfort food, and a glass of wine.
Day 10: Send a holiday letter through snail mail to someone you haven’t connected with in a while.
Cannabis in palliative care: current challenges and practical recommendations
Pain and symptom control challenges are common in palliative care, and the search for other therapeutic strategies is ongoing. Unfortunately, patients and their caregivers are receiving little information or support from healthcare providers regarding the increasingly popular cannabinoid-based medicines (CBM). Clinicians, meanwhile, feel understandably perplexed by the discrepancy between the available evidence and the rapid interest in which patients and their families have demonstrated for CBM. There is an urgent need to address the many challenges that are delaying the appropriate integration of CBM into clinical practice, notwithstanding the obvious need for a solid general knowledge of pharmacology, mechanism of action and available clinical evidence supporting its use. The authors will address these challenges and provide practical recommendations regarding patient assessment for the use of CBM. The authors will also make suggestions regarding patient expectations in order to define clear objectives, review the necessary precautions prior to initiating treatment, aid in selecting the appropriate strain and route of administration as well as establishing proper titration and monitoring protocols. The authors will also discuss the lesser known but potentially therapeutic psychoactive effects of cannabis. As this class of therapeutic agents are likely to play a major role in palliative medicine in the near future, clinicians would benefit from familiarizing themselves with CBM and we can expect that patients and their caregivers will appreciate receiving support in their search for safe and effective therapeutic alternatives.
Keywords: Medical cannabis; cannabinoids; palliative care; quality of life; review; symptom control.
A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment
Background: Peripheral neuropathic pain (PNP) associated with allodynia poses a significant clinical challenge. The efficacy of Δ(9) -tetrahydrocannabinol/cannabidiol (THC/CBD) oromucosal spray, a novel cannabinoid formulation, was investigated in this 15-week randomized, double-blind, placebo-controlled parallel group study.
Methods: In total, 303 patients with PNP associated with allodynia were screened; 128 were randomized to THC/CBD spray and 118 to placebo, in addition to their current analgesic therapy. The co-primary efficacy endpoints were the 30% responder rate in PNP 0-10 numerical rating scale (NRS) score and the mean change from baseline to the end of treatment in this score. Various key secondary measures of pain and functioning were also investigated.
Results: At the 30% responder level, there were statistically significant treatment differences in favour of THC/CBD spray in the full analysis (intention-to-treat) dataset [p = 0.034; 95% confidence interval (CI): 1.05-3.70]. There was also a reduction in mean PNP 0-10 NRS scores in both treatment groups that was numerically higher in the THC/CBD spray group, but which failed to reach statistical significance. Secondary measures of sleep quality 0-10 NRS score (p = 0.0072) and Subject Global Impression of Change (SGIC) (p = 0.023) also demonstrated statistically significant treatment differences in favour of THC/CBD spray treatment.
Conclusions: These findings demonstrate that, in a meaningful proportion of otherwise treatment-resistant patients, clinically important improvements in pain, sleep quality and SGIC of the severity of their condition are obtained with THC/CBD spray. THC/CBD spray was well tolerated and no new safety concerns were identified.